

FDA Clears Koios Medical Smart Ultrasound® AI Software for Thyroid and Breast Cancer Diagnosis.

AI enabled software cleared for use by physicians interpreting ultrasound exams. Improves cancer detection with fewer false positives and avoidable procedures.



NEW YORK CITY, NEW YORK, UNITED

STATES OF AMERICA, December 20, 2021 /EINPresswire.com/ -- Koios Medical, a fast-growing developer of medical device software, announced it received FDA clearance for Koios DS, an artificial intelligence (AI) based software platform used to diagnose thyroid and breast cancer.

The new system, built using ultrasound data from a network of 48 sites around the world, aids physicians in accurately diagnosing disease and improves speed to treatment while reducing avoidable surgical procedures.



“Thyroid DS is a game changer for thyroid ultrasound imaging...” ”

Dr. Shah Islam

In the US alone, breast and thyroid cancers combine for over 375,000 diagnosed cases annually. Over 2.2 million biopsy procedures of breast and thyroid tissue are

performed, yet tens of thousands of cancers still go undetected.

“Thyroid DS is a game changer for thyroid ultrasound imaging. Not only will it aid diagnosis of thyroid cancer it will allow for more standardized and reproducible reporting of thyroid nodules preventing potentially unwarranted biopsies on benign lesions” says Dr. Shah Islam, National Hospital for Neurology & Neurosurgery, London.

Breast cancer is the second most diagnosed cancer in women worldwide. An ultrasound exam is the standard of care for women with dense breast tissue.

Thyroid disease is one of the most complex and challenging radiological interpretations. Diagnostic uncertainty drives a high level of variability across physicians and results in surgical procedures, downstream cost, risk of complication and physician burn-out. The company performed studies that proved physicians using Koios DS software dramatically improved

accuracy, consistency, and efficiency.

Physicians' thyroid cancer detection rates jumped by up to 14% while simultaneously reducing false positive biopsy orders by over 35%. Interpretation variability was lowered by over 50% and time spent per case dropped by 24%.

"The typical decision-making paradigm relies on tradeoffs; trading sensitivity for specificity, efficiency for thoroughness, but the only thing enforcing this paradigm is the inability to shift off of these tradeoff curves in place of shifting along them. This novel software demonstrates that using AI for decision support physicians can make clinically meaningful shifts in performance improving interpretation efficacy and diagnostic performance, improving sensitivity and reducing false positives. It is exciting to bring these innovations to physicians and ultimately their patients to elevate the level of care broadly" says Dr. Lev Barinov, VP of Clinical Excellence

The patented AI software aligns Koios DS AI generated findings directly to the American College of Radiology's BI-RADS® and TI-RADS® rating systems as well as the American Thyroid Association's system for tissue classification, scoring and patient management.

The AMA recently announced new CPT Category 3 codes for whenever Koios DS software is utilized interpreting, classifying and reporting traditional ultrasound exams.

"The ability of physicians and health systems to now code and bill for the use of this innovative and effective technology will most certainly accelerate adoption, putting the software into the hands of physicians for the benefit of patients nationwide", says Graham Anderson, Koios Medical CFO.

The rigor of the FDA clearance process required that Koios DS be proven to accurately interpret images from all major ultrasound hardware manufacturers. The software is compatible with major PACS workstation viewers and integrated into [GE Healthcare's](#) LOGIQ E10 ultrasound scanner. The system enables real-time decision-making with results that can be exported directly into a patient's record and all major reporting systems, reducing errors and saving time.

"Koios obtaining FDA clearance for their DS thyroid AI algorithms is another positive sign in the acceptance of AI the day-to-day radiology workflow. In clinical trials DS 3.0 has been shown to improve the confidence level of the radiologist's diagnosis by providing a "second set of eyes" on the study and making sure nothing was missed. This also provides the patient with a higher level of confidence in the accuracy of the interpretation as well." says radiology industry expert and AI consultant Michael Cannavo.

Koios DS Breast has been commercially available in the US since 2018 and across Europe, the Middle East, and South America since early 2021 and recently received approval from Health Canada.

“The loss of life globally to cancers found too late, or misdiagnosed, is tragic. When combined with the millions wasted on avoidable procedures we are compelled to relentlessly innovate, building powerful AI models directly into easy-to-use software. This new FDA clearance means physicians are now poised to save tens of thousands of lives while freeing up precious time and resources that can be used more effectively and elevate quality of life.” says Koios Medical CEO Chad McClennan.

About Koios Medical:

Koios Medical develops medical software to assist physicians interpreting ultrasound images and applies deep machine learning methods to the process of reaching an accurate diagnosis. The Koios DS platform uses advanced AI algorithms to assist in the early detection of disease while reducing recommendations for biopsy of benign tissue. Patented technology saves physicians time, helps improve patient outcomes, and reduces healthcare costs. Koios DS (decision support) is presently focused on the breast and thyroid cancer diagnosis market. Women with dense breast tissue (over 40% in the US) often require an alternative to mammography for diagnosis. Ultrasound is a widely available and effective alternative to mammography using no ionizing radiation and is a standard of care for cancer diagnosis.

Tonja Haugh

Koios Medical, Inc

+1 716-574-2165

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/558669023>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.